Nature Reviews Gastroenterology & Hepatology

Papers
(The H4-Index of Nature Reviews Gastroenterology & Hepatology is 73. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Regulating protease homeostasis in irritable bowel syndrome641
Hybrid EASL Congress 2023484
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity447
Zolbetuximab treatment in metastatic gastric cancer425
2023 FDA approvals in gastroenterology and hepatology404
Western lifestyle, metaflammation and the cell of origin of colon cancer349
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection340
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis326
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology313
Digestive Disease Week 2022305
Mapping neuroimmune interactions in the gut301
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa282
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed275
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection266
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis257
Nomenclature of HBV core protein-targeting antivirals252
Artificial intelligence and automation in endoscopy and surgery239
Leveraging diet to engineer the gut microbiome216
Oral microbiome therapy efficacious for recurrent C. difficile infection201
Hepatic IRF3 in glucose intolerance201
Wound healing in the colon191
A crucial Fusobacterium nucleatum clade in colorectal cancer185
GWAS reveals variants for alcohol-related hepatocellular carcinoma176
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges169
Metastatic pancreatic cancer and the liver168
Decoding therapy resistance in liver tumours: a giant leap161
A deep dive into the submerged ‘coeliac iceberg’159
New understanding of hepatobiliary MRI157
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract156
Inflammatory bowel disease in pregnancy and breastfeeding152
The global burden of coeliac disease: opportunities and challenges151
Bacteriophages and their potential for treatment of gastrointestinal diseases151
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation145
Advancing on pancreatic cancer144
Dietary carbohydrates and fats in nonalcoholic fatty liver disease143
HDCA ameliorates NAFLD in mice140
Hepatocyte-derived biomarkers in alcohol-related cirrhosis139
Integrated systems approach to identify environmental factors in intestinal inflammation139
Metabolic diseases in the East Asian populations133
Therapeutic base editing in the adult liver128
Lanifibranor and NASH resolution127
Probiotics for preterms: sharing complex decision-making121
Implications of the evolving knowledge of the genetic architecture of MASLD118
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases111
Medical therapy of paediatric inflammatory bowel disease110
Preventing the progression of cirrhosis to decompensation and death108
Estimating dietary intake from human stool DNA108
Characterizing the genomic landscape of colorectal cancer106
SSRIs and depression: role of gut–brain communication101
Human intestinal B cells in inflammatory diseases101
The path to successful hepatitis C elimination in Spain100
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management100
Transglutaminase 2 inhibitor for coeliac disease100
Current and future colorectal cancer screening strategies97
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook97
ECCO’2496
Transforming the landscape of liver cancer detection and care95
Author Correction: Hepatic immune regulation and sex disparities92
Yeast probiotics for the treatment of IBD91
A single-cell atlas of fibroblasts: one size does not fit all91
NAFLD prevalence in older patients with T2DM89
Phase III results for first-line treatment for metastatic colorectal cancer88
Gut microbiome and autism spectrum disorder85
Microbiota and colorectal cancer — controlling for confounders challenges associations85
Enteric nervous system transfers stress to the gut83
GLP1R agonists in NAFLD: a promising therapy on the horizon82
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance82
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’80
Publisher Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics79
Hepatic glucose metabolism in the steatotic liver76
Artificial intelligence in liver cancer — new tools for research and patient management76
Foundations of gastrointestinal-based drug delivery and future developments76
Neutrophils as potential therapeutic targets in hepatocellular carcinoma76
Hepatic inflammatory responses in liver fibrosis73
Immunoregulatory role of enteric glia73
0.15672707557678